About Nova Sud Pharmaceuticals Private Limited
Data last updated:
Nova Sud Pharmaceuticals Private Limited is a private limited company based in Hyderabad, Telangana, India, a subsidiary of Medplus Health Services Limited. It operates in the pharmaceutical retail and distribution segment of the pharmaceuticals sector. It was incorporated on 12 October 2007 and has been in existence for over 19 years.
The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN U24232TG2007PTC055895. Its GSTIN is 36AAFCP1772L1Z3 (Telangana).
The company has an authorised share capital of ₹6.86 Cr and a paid-up capital of ₹6.86 Cr. It was formerly known as Panindia Pharma Distributors Private Limited. It is led by directors including Phani Srinivas Ramella and Bhaskar Reddy Cherukupalli.
Its last annual general meeting (AGM) was held on 05 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at No.3 – 4 – 97/Q/Nr/ Within St. John Seminary Compound Ramanthpur, Hyderabad, Telangana, India – 500013.
As per the financials filed for FY 2025, the company reported a revenue of ₹12.7 Lakh, a decline of 95% compared to the previous year. For the same year it recorded a net loss of ₹5.8 Lakh (net margin -45.7%) and EBITDA of -₹5.2 Lakh (EBITDA margin -40.9%). Revenue has declined at a compounded annual rate (CAGR) of 59% over three years.
Its group structure includes 5 subsidiaries.
The company has 8 deals on record (5 funding rounds, 2 acquisitions, 1 secondary share transfer), with disclosed funding of ₹5.35 Cr; the latest was in March 2021. Its 10 peer companies in the Pharma industry (Pharma Retail and Distribution, Pharmaceuticals) are compared by revenue, 5 larger and 5 smaller; the largest is Rexon Laboratories Limited with revenue of ₹12.74 Lakh.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website medplusindia.com.
CIN History of Nova Sud Pharmaceuticals Private Limited
Nova Sud Pharmaceuticals has one previous CIN (Corporate Identification Number): U24232AP2007PTC055895. The current CIN is U24232TG2007PTC055895, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24232TG2007PTC055895 | Current |
| U24232AP2007PTC055895 | Previous |
- EmailLocked
- TelephoneLocked
- Website
- Social Media
- Apps
- Registered AddressNo.3 – 4 – 97/Q/Nr/ Within St. John Seminary Compound Ramanthpur, Hyderabad, Telangana, India – 500013
- IndustryPharma, Pharmaceutical Retailers & Distributors
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Business Activity of Nova Sud Pharmaceuticals Private Limited
The main business activity of Nova Sud Pharmaceuticals is trade. In detail, this covers wholesale trading.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Nova Sud Pharmaceuticals Private Limited FY 2025 filings available
Nova Sud Pharmaceuticals Private Limited reported revenue of ₹12.7 Lakh (down 95% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR) of Nova Sud Pharmaceuticals Private Limited
Revenue has declined at a compounded annual rate (CAGR) of 59% over three years, including a 95% fall in the latest year. EBITDA fell 117% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Nova Sud Pharmaceuticals Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | •••• | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | -₹5.2 Lakh | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | -₹5.8 Lakh | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Nova Sud Pharmaceuticals Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | -40.9% | •••• | •••• | •••• | •••• |
| Net Profit Margin | -45.7% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Nova Sud Pharmaceuticals are in the company report.
Financial statements from 2015
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Board of Directors of Nova Sud Pharmaceuticals Private Limited
Nova Sud Pharmaceuticals has 3 current directors and 5 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Phani Srinivas Ramella Also directs: Sai Sridhar Pharma Private Limited, Deccan Medisales Private Limited, Medplus Insurance Brokers Private Limited and 3 more | Director | 31 Jul 2014 | 12 Years 2 Months | Current |
| Bhaskar Reddy Cherukupalli Also directs: Agilepro (India) Ventures LLP, Medplus Health Services Limited, Wynclark Pharmaceuticals Private Limited and 5 more | Director | 26 May 2024 | 2 Years 4 Months | Current |
| Satya Murali Krishna Kammila Also directs: Wynclark Pharmaceuticals Private Limited, Clearancekart Private Limited, Kalyani Meditimes Private Limited and 5 more | Director | 29 Sep 2021 | 5 Years 0 Months | Current |
Peer Comparison of Nova Sud Pharmaceuticals Private Limited
Nova Sud Pharmaceuticals Private Limited is compared with the companies closest to it by revenue in the Pharma industry (Pharma Retail and Distribution, Pharmaceuticals). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Rexon Laboratories Limited | ₹12.74 Lakh (FY 2025) | •••• | •••• | -93.0% | •••• | Jalandhar, Punjab, India |
| Minecure Pharmaceuticals Private Limited (OPC) | ₹12.74 Lakh (FY 2020) | •••• | •••• | 3335.0% | •••• | Bhubaneswar, Odisha, India |
| Yanelly Pharmaceuticals Private Limited | ₹12.73 Lakh (FY 2024) | •••• | •••• | 10.0% | •••• | Bhopal, Madhya Pradesh, India |
| Medniqa Pharmaceuticals Private Limited | ₹12.72 Lakh (FY 2025) | •••• | •••• | 1320.0% | •••• | Ahmedabad, Gujarat, India |
| Redsear Pharmaceuticals Private Limited | ₹12.72 Lakh (FY 2025) | •••• | •••• | -21.0% | •••• | Jaipur, Rajasthan, India |
| Nova Sud Pharmaceuticals Private Limited this company | ₹12.7 Lakh (FY 2025) | •••• | •••• | -95.0% | •••• | Hyderabad, Telangana, India |
| Denmarc Remedies Private Limited | ₹12.69 Lakh (FY 2025) | •••• | •••• | -37.0% | •••• | Delhi, India |
| Alexy Cares Pharmaceuticals Private Limited | ₹12.69 Lakh (FY 2025) | •••• | •••• | -16.0% | •••• | New Delhi, Delhi, India |
| Caprion Pharma Private Limited | ₹12.68 Lakh (FY 2024) | •••• | •••• | •••• | Jaipur, Rajasthan, India | |
| Orenzy Pharmaceuticals Private Limited | ₹12.68 Lakh (FY 2024) | •••• | •••• | -36.0% | •••• | Pune, Maharashtra, India |
| Adchem Intl Trade India Private Limited | ₹12.67 Lakh (FY 2025) | •••• | •••• | 1422.0% | •••• | Nalagarh, Himachal Pradesh, India |
Peers are the five companies nearest above and the five nearest below Nova Sud Pharmaceuticals by revenue in the Pharma industry (Pharma Retail and Distribution, Pharmaceuticals), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Auditor Details of Nova Sud Pharmaceuticals Private Limited
Nova Sud Pharmaceuticals Private Limited is audited by Gphk & Associates for the financial year 2023.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| Gphk & Associates | Locked | Locked | Locked |
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Ownership and Shareholding of Nova Sud Pharmaceuticals Private Limited
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of Nova Sud Pharmaceuticals Private Limited
Nova Sud Pharmaceuticals Private Limited does not have any charges (loans) registered with the Registrar of Companies.
Deals & Funding of Nova Sud Pharmaceuticals Private Limited
Nova Sud Pharmaceuticals Private Limited has 8 deals on record (5 funding rounds, 2 acquisitions, 1 secondary share transfer), with disclosed funding of ₹5.35 Cr; the latest was in March 2021.
Deals on record (5 of 8)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Mar 2021 | Funding round | ₹50 Lakh | Investors: Medplus Health Services Limited |
| Oct 2017 | Funding round | ₹2 Cr | Investors: Medplus Health Services Limited |
| Mar 2016 | Funding round | ₹1.7 Cr | Investors: Medplus Health Services Limited |
| Jan 2015 | Funding round | ₹1 Cr | Investors: Medplus Health Services Limited |
| Mar 2014 | Funding round | ₹15 Lakh | Investors: Medplus Health Services Limited |
Full deal history
All 8 deals with amounts, valuations, instruments and every party are in the company report.
- Every funding round and share transfer
- Amounts and valuations
- Investors, buyers and sellers
- Instruments and deal dates
Verified entity values are shown only after access is granted.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Employees and EPFO Compliance at Nova Sud Pharmaceuticals Private Limited
Employment history and EPFO contributions of people linked to Nova Sud Pharmaceuticals.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Group Structure of Nova Sud Pharmaceuticals Private Limited
Nova Sud Pharmaceuticals has 5 subsidiary companies. This group structure data is as of FY 2023. The table lists each entity with its relationship and holding.
| Company Name | CIN | Shares Held |
|---|---|---|
| Sai Sridhar Pharma Private Limited | U24232TG2007PTC055902 | Locked |
| Deccan Medisales Private Limited | U51397KA2011PTC059204 | Locked |
| Venkata Krishna Enterprises Private Limited | U51909TG2010PTC071012 | Locked |
| Shri Banashankari Pharma Private Limited | U74900KA2014PTC074302 | Locked |
| Sidson Pharma Distributors Private Limited | U74900TG2014PTC092145 | Locked |
Showing major subsidiaries. Total: 5.
Recent Activity on Nova Sud Pharmaceuticals Private Limited
Nova Sud Pharmaceuticals Private Limited has 8 board changes on record since 2014: 3 appointments and 5 cessations. The latest: Bhaskar Reddy Cherukupalli was appointed as Director on 26 May 2024.
Credit Ratings, Litigation & Regulatory Alerts for Nova Sud Pharmaceuticals Private Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Nova Sud Pharmaceuticals Private Limited
MSME payment history
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Nova Sud Pharmaceuticals Private Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Nova Sud Pharmaceuticals Private Limited
Nova Sud Pharmaceuticals has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 36AAFCP1772L1Z3 | Telangana | Active | 05 Dec 2019 |
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Nova Sud Pharmaceuticals Private Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Nova Sud Pharmaceuticals Private Limited
Nova Sud Pharmaceuticals is an active private limited company based in Hyderabad, Telangana, India. The company works in pharmaceutical retailers and distributors, within the pharma industry. It was incorporated on 12 October 2007 (19+ years old) and is registered under CIN U24232TG2007PTC055895.
Nova Sud Pharmaceuticals reported revenue of ₹12.7 Lakh for FY 2025 (down 95% YoY).
Nova Sud Pharmaceuticals has 3 current directors:
- Phani Srinivas Ramella - Director
- Bhaskar Reddy Cherukupalli - Director
- Satya Murali Krishna Kammila - Director
Nova Sud Pharmaceuticals reported a net loss of ₹5.8 Lakh (net margin -45.7%) and EBITDA of -₹5.2 Lakh (EBITDA margin -40.9%) for FY 2025, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Nova Sud Pharmaceuticals is -59% over three years. In the latest year (FY 2025) revenue fell 95%. CAGR is the steady yearly rate that links the first and the last year.
The GSTIN of Nova Sud Pharmaceuticals is 36AAFCP1772L1Z3, registered in Telangana.
The CIN (Corporate Identification Number) of Nova Sud Pharmaceuticals is U24232TG2007PTC055895. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Nova Sud Pharmaceuticals was incorporated on 12 October 2007, making it 19+ years old. It is registered with the Registrar of Companies, Hyderabad.
Nova Sud Pharmaceuticals has 8 deals on record (5 funding rounds, 2 acquisitions, 1 secondary share transfer), with disclosed funding of ₹5.35 Cr; the latest was in March 2021.
The peers of Nova Sud Pharmaceuticals by revenue are Rexon Laboratories Limited, Minecure Pharmaceuticals Private Limited (OPC), Yanelly Pharmaceuticals Private Limited, Medniqa Pharmaceuticals Private Limited, Redsear Pharmaceuticals Private Limited and 5 more, all in the Pharma industry (Pharma Retail and Distribution, Pharmaceuticals).
Bhaskar Reddy Cherukupalli was appointed as Director on 26 May 2024. Prasad Reddy Battinapatla ceased to be Director on 25 Apr 2024. Ravi Venkat Reddy ceased to be Director on 27 Sep 2023. Nova Sud Pharmaceuticals has 8 board changes on record in total.